FIELDS HEIDI 4

What Happened

• Heidi Fields, a director of Phathom Pharmaceuticals, was granted 24,122 Restricted Stock Units (RSUs) on May 19, 2026. The award is reported as an acquisition (grant) at $0.00 per RSU, so there is no immediate cash proceeds from the transaction. Each RSU represents a contingent right to receive one share of Phathom common stock upon vesting.

Key Details

• Transaction date and type: 2026-05-19 — Grant/Award (transaction code A) of 24,122 RSUs at $0.00.
• Immediate cash value: $0 (value realized only if/when RSUs settle into shares).
• Vesting: 100% vests on the earlier of (A) the first anniversary of the grant or (B) the next annual meeting of stockholders, subject to continued board service (per filing footnote).
• Shares owned after transaction: not specified in the reported Form 4.
• Filing timeliness: Report filed May 21, 2026 for a May 19, 2026 grant — appears timely (no late-filing indicator in the record).
• Plan: Award granted under the Issuer’s Non-Employee Director Compensation Program; no 10b5-1 plan or tax-withholding instructions noted in the filing.

Context

• RSUs are compensatory awards for service; they become actual shares only upon vesting and settlement, so this is a retention/compensation event rather than an open-market purchase or sale. Such grants are common for non-employee directors and do not by themselves indicate a buy/sell signal.